Search

Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial

Jonathan Lea-Ann Tom Carapetis AM Kirkham Snelling AM MBBS FRACP FAFPHM PhD FAHMS PhD BMBS DTMH GDipClinEpid PhD FRACP Executive Director; Co-Head,

A phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of inhaled ethanol in humans as a potential treatment for respiratory tract infections

Current treatments for respiratory infections are severely limited. Ethanol's unique properties including antimicrobial, immunomodulatory, and surfactant-like activity make it a promising candidate treatment for respiratory infections if it can be delivered safely to the airway by inhalation. Here, we explore the safety, tolerability, and pharmacokinetics of inhaled ethanol in a phase I clinical trial.

Global study finds human air travel culprit for RSV variant spread

Global circulation of respiratory syncytial virus (RSV) is shaped by human air travel with travellers hosting new strains fuelling transmission across borders, an international The Kids Research Institute Australia study found.

Australia Day Honours for researchers and esteemed Elder

Four outstanding members of The Kids Research Institute Australia family – three researchers and an Aboriginal Elder co-researcher – have been named in the Australia Day Honours List for their outstanding service to research and the community.

RSV rates skyrocket among Aboriginal babies

Experts are warning Aboriginal parents in Western Australia with newborn babies to be vigilant about Respiratory Syncytial Virus (RSV) as winter progresses.

RSV vaccine for pregnant women provides protection for babies: study

A world-first study has found a new vaccine against potentially deadly respiratory syncytial virus (RSV) is safe and effective for use in pregnant women, to help protect their babies.

RSV prevention finally in reach after 20 years of research at The Kids Research Institute Australia

World-first immunisations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.

Bacterial slime causing persistent wet coughs for children

Researchers using powerful microscopes have identified bacterial slime in the lungs of some children with persistent wet coughs.

“We've wanted to vaccinate against it and now we can”: views of respiratory syncytial virus disease and immunisation held by caregivers of Aboriginal children in Perth, Western Australia

Respiratory syncytial virus (RSV) is a major cause of respiratory infection with a higher burden in Aboriginal and Torres Strait Islander infants and children. We conducted a pilot qualitative study identifying disease knowledge and willingness to immunise following the changing immunisation landscape for infant RSV in 2024.

Clinical outcomes and severity of laboratory-confirmed RSV compared with influenza, parainfluenza and human metapneumovirus in Australian children attending secondary care

Acute lower respiratory infections (ALRIs) are a major contributor to the global infectious disease burden and a common cause of hospitalisation for children under 2 years. We compared clinical severity in children hospitalised with respiratory syncytial virus (RSV), parainfluenza virus (PIV), human metapneumovirus (hMPV) and influenza virus (IFV).